ClinicalTrials.gg
RecruitingNCT07008898Updated Feb 17, 2026

Sequence of Midurethral Sling Placement During Robotic Sacrocolpopexy

An interventional study of Midurethral sling placed before robotic sacrocolpopexy and Midurethral sling placed after robotic sacrocolpopexy in Stress Incontinence Female and Pelvic Organ Prolapse, sponsored by University of Alabama at Birmingham. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 195 studies in Pelvic Organ Prolapse with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Pelvic Organ Prolapse · United States.

Planned enrollment
46th of 133
110 · median 78
Started
2025
with 5 others
No phase
90 of 195
6 open now
Primary completion
2027-05
later than 13 of 22 live
Registered
186th of 195
by date

Among the 195 studies in Pelvic Organ Prolapse with a site in United States, this one is the 46th largest by planned enrollment of the 133 interventional ones that give a count, is one of 6 that started in 2025, is one of 90 with no phase, reaches primary completion later than 13 of the 22 other live ones, and was the 186th registered.

Pelvic Organ Prolapse

522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.

Browse Pelvic Organ Prolapse studies →

Open to participants now

12 of the 195 studies in Pelvic Organ Prolapse with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Pelvic Organ Prolapse with a site in United States, or all of them as a file.
02

Study summary

This study looks at the best time to place a midurethral sling (MUS), which is a small piece of mesh used to treat stress urinary incontinence (SUI) (leaking urine when you cough, laugh, or exercise). The sling is placed during a type of surgery called robotic sacrocolpopexy (RSC). This surgery helps fix pelvic organ prolapse, when organs like the bladder or uterus drop from their normal place.

Doctors can place the sling either before or after they lift and support the top of the vagina during surgery, but they aren't sure which timing works better. In this study, investigators are comparing what is the best time to place the sling, how the patient feels after surgery and if a patient's symptoms got better or worse.

Read the detailed description

Investigators will conduct a prospective, randomized, noninferiority trial on patients undergoing retropubic midurethral sling (RP MUS) placement at the time of robotic-assisted sacrocolpopexy (RSC).

Patients scheduled to undergo retropubic midurethral sling placement at the time of robotic- assisted sacrocolpopexy will be invited to participate during regularly scheduled preoperative visits with their urogynecologic provider. Participants will be randomized to receive RP MUS before RSC or after RSC. Randomization will be conducted in RedCap. Randomization will be performed using a variable permutated block randomization scheme. The Randomization window will be +/- 4 days before their scheduled surgery, and patients will be blinded to sequence of MUS placement intraoperatively.

03

Conditions studied

  • Stress Incontinence Female
  • Pelvic Organ Prolapse

Keywords

  • Stress incontinence
  • Pelvic organ prolapse
  • Midurethral sling
  • Sucess rates
  • Complication rates
  • Patient satisfaction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • Able to speak and read English and Spanish

    • Diagnosis of pelvic organ prolapse stage 2-4
    • Planning to undergo a robotic-assisted sacrocolpopexy
    • Demonstrable SUI (either by CST, with or without prolapse reduction, or UDS) within the year prior to enrollment
    • Planning to undergo concomitant SUI correction with MUS at the time of RSC

Exclusion criteria

Exclusion Criteria:

  • Less than 18 years of age
  • Unable to speak and read English or Spanish
  • No diagnosis of SUI (prophylactic slings)
  • History of prior surgery for SUI
  • Bladder capacity \<200 mL or post-void residual (PVR) >150 mL
  • Current genitourinary fistula or urethral diverticulum
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
110 participants (estimated)

Study arms

  • Active comparator
    Midurethral sling placed before robotic sacrocolpopexy

    Midurethral sling placed after robotic sacrocolpopexy

    Procedure: Midurethral sling placed before robotic sacrocolpopexy

  • Active comparator
    Midurethral sling placed after robotic sacrocolpopexy

    Procedure: Midurethral sling placed after robotic sacrocolpopexy

Interventions

  • ProcedureMidurethral sling placed before robotic sacrocolpopexy

    Sequence of midurethral sling placement (before or after suspension of the vaginal apex) during robotic sacrocolpopexy is largely surgeon-dependent and dictated by training and experience. This study will examine whether there are any differences in continence and patient satisfaction between patients in whom slings are placed prior to suspension of the vaginal apex during robotic sacrocolpopexy versus after.

  • ProcedureMidurethral sling placed after robotic sacrocolpopexy

    Sequence of midurethral sling placement (before or after suspension of the vaginal apex) during robotic sacrocolpopexy is largely surgeon-dependent and dictated by training and experience. This study will examine whether there are any differences in continence and patient satisfaction between patients in whom slings are placed prior to suspension of the vaginal apex during robotic sacrocolpopexy versus after.

06

What researchers measure

Primary outcomes

  1. Urinary Distress Index, Short Form (UDI-6) scores at 3 months postoperative

    The primary outcome will be change between baseline and 3 months stress urinary incontinence symptoms as measured by the UDI-6. Scores for the UDI-6 range from 0 to 100 has an MCID of 5.8, with higher scores indicating worse symptoms.

    Time frame: 3 months

Secondary outcomes

  1. Provocative stress test results at 6 weeks postoperative

    Patients will be examined in the office during 6-week postoperative visit as is routine practice and assess for leakage of urine during empty supine provocative cough stress test.

    Time frame: 6 weeks

  2. Need for re-treatment for stress urinary incontinence (SUI) at 6 weeks postoperative

    If recurrent stress urinary incontinence is noted to be present at 6-weeks postoperative, whether or not patients elect to proceed with additional treatment will be assessed.

    Time frame: 6 weeks

  3. Change in total Pelvic Organ Prolapse/Incontinence Sexual Questionnaire (PISQ-IR) at 3 months postoperative

    PISQ-IR will be administered at enrollment and at 3 months postoperative, and scores will be compared.

    Time frame: 3 months

  4. Change in total Incontinence Impact Questionnaire, Short Form (IIQ-7) scores at 3 months postoperative

    IIQ-7 will be administered to patients at enrollment and at 3 months postoperative, and scores at these two time points will be compared.

    Time frame: 3 months

  5. Complications (graded as Clavien Dindo)

    Complications occurring during or after concomitant RSC and RP MUS will be recorded between both groups and compared.

    Time frame: 6 weeks

  6. Objective surgical data such as operative time

    Objective surgical data such as operative time will be recorded between both groups and compared.

    Time frame: 6 weeks

  7. Objective surgical data such as estimated blood loss (EBL)

    Objective surgical data such as estimated blood loss (EBL) will be recorded between both groups and compared.

    Time frame: 6 weeks

  8. Patient satisfaction (a decision scale and decision regret scale)

    A decision regret scale will be administered to patients at 3 months postoperative, and scores will be compared between the two groups to assess if any difference in patient satisfaction exists.

    Time frame: 3 months

  9. Patient satisfaction (Patient Global Impression of Improvement (PGI-I) for Incontinence)

    The PGI-I will be administered to all patients at 3 months to assess patient satisfaction with the procedure performed; any differences between groups in patient satisfaction will be assessed with this outcome.

    Time frame: 3 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Minimum necessay IPD will be shared with other researchers if trial is expanded to multiple sites.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.

Of 162 non-industry interventional studies with no phase under Pelvic Organ Prolapse, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 22 months is close to that.

Counting every sponsor, half of 179 studies reached it within 23 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jun 6, 2025
StartActual
Jul 8, 2025
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07008898
Responsible party
Gabriela Halder (Assistant Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Jun 6, 2025
Start date
Jul 8, 2025
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Martha K Coghlan, MD
Contact
mkcoghlan@uabmc.edu
6019883613
Gabriela E Halder, MD, MPH
Contact
gehalder@uabmc.edu
205-975-0304
Gabriela E Halder, MD, MPH
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion